恆邦股份(002237.SZ):5%以上股東恆邦集團及其一致行動人持股比例被動稀釋2.5%
格隆匯11月30日丨恆邦股份(002237.SZ)公佈,經中國證券監督管理委員會《關於核准山東恆邦冶煉股份有限公司非公開發行股票的批覆》核准,公司非公開發行了2.38億股人民幣普通股(A股),新增股份將於2020年11月30日在深圳證券交易所上市,本次發行後,公司總股本將由9.104億股增至11.48億股。本次發行導致恆邦集團及其一致行動人王信恩、王家好持股比例被動稀釋2.50%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.